YU33702A - Antagonisti adenozinskih receptora i postupci za njihovu izradu - Google Patents

Antagonisti adenozinskih receptora i postupci za njihovu izradu

Info

Publication number
YU33702A
YU33702A YU33702A YUP33702A YU33702A YU 33702 A YU33702 A YU 33702A YU 33702 A YU33702 A YU 33702A YU P33702 A YUP33702 A YU P33702A YU 33702 A YU33702 A YU 33702A
Authority
YU
Yugoslavia
Prior art keywords
making
methods
same
receptor antagonists
adenosine receptor
Prior art date
Application number
YU33702A
Other languages
English (en)
Inventor
James E. Dowling
Carol Ensinger
Gnana Sambandam Kumaravel
Russel C. Petter
Original Assignee
Biogen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc. filed Critical Biogen Inc.
Publication of YU33702A publication Critical patent/YU33702A/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Pronalazak se odnosi na jedinjenja formule (I): koja su se pokazala kao veoma jaki i selektivni inhibitori adenozin A1 receptora. Ova jedinjenja se mogu koristiti u priozvodnji leka za tretiranje i/ili sprečavanje brojnih oboljenja, uključujući poremećaje srca i krvnih sudova, degenerativni poremećaj centralnog nervnog sistema, neki poremećaj disanja i brojna oboljenja za koja je lečenje diureticima pogodno.[The invention is based on the discovery that compounds of Formula (I), are unexpectedly highly potent and selective inhibitors of the adenosine A1 receptor. Adenosine A1 antagonists can be useful in the prevention and/or treatment of numerous diseases, including cardiac and circulatory disorders, degenerative disorders of the central nervous system, respiratory disorders, and many diseases for which diuretic treatment is suitable. In one embodiment, the invention features a compound of formula (I), wherein R3 is selected from particular bicycloheptyl, bicyclooctyl, tricycloheptyl and tricyclooctyl groups.
YU33702A 1999-11-12 2000-11-13 Antagonisti adenozinskih receptora i postupci za njihovu izradu YU33702A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16528399P 1999-11-12 1999-11-12

Publications (1)

Publication Number Publication Date
YU33702A true YU33702A (sh) 2005-03-15

Family

ID=22598257

Family Applications (1)

Application Number Title Priority Date Filing Date
YU33702A YU33702A (sh) 1999-11-12 2000-11-13 Antagonisti adenozinskih receptora i postupci za njihovu izradu

Country Status (33)

Country Link
US (4) US6605600B1 (sh)
EP (2) EP1230241B1 (sh)
JP (1) JP2003513976A (sh)
KR (1) KR100845488B1 (sh)
CN (1) CN1187354C (sh)
AT (1) ATE353328T1 (sh)
AU (1) AU784528B2 (sh)
BG (1) BG106693A (sh)
BR (1) BR0015540A (sh)
CA (1) CA2390590C (sh)
CY (1) CY1106560T1 (sh)
CZ (1) CZ20021615A3 (sh)
DE (1) DE60033310T2 (sh)
DK (1) DK1230241T3 (sh)
EA (1) EA010260B1 (sh)
EE (1) EE200200248A (sh)
ES (1) ES2281367T3 (sh)
GE (1) GEP20043267B (sh)
HK (1) HK1049153B (sh)
HU (1) HUP0203371A3 (sh)
IL (1) IL149486A0 (sh)
IS (1) IS6380A (sh)
MX (1) MXPA02004795A (sh)
NO (1) NO20022237L (sh)
NZ (2) NZ519427A (sh)
PL (1) PL198156B1 (sh)
PT (1) PT1230241E (sh)
SK (1) SK6622002A3 (sh)
TR (1) TR200301062T2 (sh)
UA (1) UA77937C2 (sh)
WO (1) WO2001034604A2 (sh)
YU (1) YU33702A (sh)
ZA (1) ZA200203702B (sh)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI229674B (en) 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
BR0015545A (pt) * 1999-11-12 2002-08-06 Biogen Inc Policicloalquilpurinas como antagonistas dos receptores para adenosina
PT1230241E (pt) * 1999-11-12 2007-05-31 Biogen Idec Inc Antagonistas do receptor de adenosina e métodos de fabrico e uso dos mesmos
SG131115A1 (en) * 2002-06-12 2007-04-26 Biogen Idec Inc Method of treating ischemia reperfusion injury using adenosine receptor antagonists
AU2003261206A1 (en) * 2002-07-19 2004-02-09 Aryx Therapeutics Xanthine derivatives having adenosine a1-receptor antagonist properties
US20040229901A1 (en) * 2003-02-24 2004-11-18 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist
CA2522323C (en) * 2003-04-14 2009-09-15 Pfizer Products Inc. 3-azabicyclo[3.2.1]octane derivatives as opioid receptor ligands
MXPA05011371A (es) * 2003-04-25 2005-12-01 Novacardia Inc Metodo para mejorar la diuresis en individuos con la funcion renal deteriorada.
WO2005009343A2 (en) * 2003-06-06 2005-02-03 Endacea, Inc. A1 adenosine receptor antogonists
US20070208040A1 (en) * 2006-03-02 2007-09-06 Elfatih Elzein A2a adenosine receptor antagonists
CN101420958A (zh) * 2006-04-06 2009-04-29 挪瓦卡尔迪阿公司 共投与腺苷a1受体拮抗剂和抗惊厥药
NZ573735A (en) 2006-05-19 2011-10-28 Abbott Lab Cns active fused bicycloheterocycle substituted azabicyclic alkane derivatives
EP2035009A1 (en) * 2006-06-16 2009-03-18 Novacardia, Inc. Prolonged improvement of renal function comprising infrequent administration of an aa1ra
US20080242684A1 (en) * 2007-03-29 2008-10-02 Howard Dittrich Methods of administration of adenosine a1 receptor antagonists
WO2008121893A1 (en) * 2007-03-29 2008-10-09 Novacardia, Inc. Methods of treating heart failure and renal dysfunction in individuals with an adenosine a1 receptor antagonist
US20090228097A1 (en) * 2008-03-07 2009-09-10 Abbott Cardiovascular Systems Inc. A1 Adenosine Receptor Antagonist-Coated Implantable Medical Device
CN114790164B (zh) 2021-08-13 2022-12-27 苏州璞正医药有限公司 一种取代的异吲哚啉-1,3-二酮类pde4抑制剂及其药物用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3155664A (en) * 1959-11-13 1964-11-03 Endo Lab Derivatives of theophylline
DE3843117A1 (de) 1988-12-22 1990-06-28 Boehringer Ingelheim Kg Neue xanthinderivate mit adenosin-antagonistischer wirkung
JPH06102662B2 (ja) 1989-09-01 1994-12-14 協和醗酵工業株式会社 キサンチン誘導体
US5290782A (en) 1989-09-01 1994-03-01 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
EP0423805B1 (en) 1989-10-20 2000-08-23 Kyowa Hakko Kogyo Kabushiki Kaisha Condensed purine derivatives
DE4019892A1 (de) * 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
CA2061544A1 (en) 1991-02-25 1992-08-26 Fumio Suzuki Xanthine compounds
EP0541120B1 (en) 1991-11-08 1999-05-26 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives for the treatment of dementia
EP0556778A3 (en) 1992-02-17 1993-11-24 Kyowa Hakko Kogyo Kk Xanthine derivatives
US5342841A (en) 1992-03-12 1994-08-30 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
TW252044B (sh) 1992-08-10 1995-07-21 Boehringer Ingelheim Kg
WO1994016702A1 (en) 1993-01-26 1994-08-04 Kyowa Hakko Kogyo Co., Ltd. Remedy for irregular bowel movement
US5395836A (en) 1993-04-07 1995-03-07 Kyowa Hakko Kogyo Co., Ltd. 8-tricycloalkyl xanthine derivatives
US5446046A (en) * 1993-10-28 1995-08-29 University Of Florida Research Foundation A1 adenosine receptor agonists and antagonists as diuretics
WO1998057644A1 (fr) 1997-06-16 1998-12-23 Kyowa Hakko Kogyo Co., Ltd. Agent de prevention et remede contre la nephropathie induite par les medicaments
WO1998057645A1 (fr) 1997-06-16 1998-12-23 Kyowa Hakko Kogyo Co., Ltd. Medicament contre l'oedeme hepatique
DE19816857A1 (de) 1998-04-16 1999-10-21 Boehringer Ingelheim Pharma Neue unsymmetrisch substituierte Xanthin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP0955301A3 (en) * 1998-04-27 2001-04-18 Pfizer Products Inc. 7-aza-bicyclo[2.2.1]-heptane derivatives, their preparation and use according to their affinity for neuronal nicotinic acetylcholine receptors
WO2000001388A1 (fr) 1998-07-02 2000-01-13 Kyowa Hakko Kogyo Co., Ltd. Medicaments antidiabetiques
BR0015545A (pt) * 1999-11-12 2002-08-06 Biogen Inc Policicloalquilpurinas como antagonistas dos receptores para adenosina
PT1230241E (pt) * 1999-11-12 2007-05-31 Biogen Idec Inc Antagonistas do receptor de adenosina e métodos de fabrico e uso dos mesmos

Also Published As

Publication number Publication date
AU2042101A (en) 2001-06-06
ES2281367T3 (es) 2007-10-01
EP1775297A2 (en) 2007-04-18
CY1106560T1 (el) 2012-01-25
KR100845488B1 (ko) 2008-07-10
CN1399636A (zh) 2003-02-26
NO20022237L (no) 2002-07-12
NO20022237D0 (no) 2002-05-10
TR200301062T2 (tr) 2003-09-22
ZA200203702B (en) 2003-10-29
EP1230241A2 (en) 2002-08-14
PT1230241E (pt) 2007-05-31
DK1230241T3 (da) 2007-06-04
EE200200248A (et) 2003-06-16
AU784528B2 (en) 2006-04-27
UA77937C2 (en) 2007-02-15
BG106693A (bg) 2003-01-31
PL356044A1 (en) 2004-06-14
JP2003513976A (ja) 2003-04-15
KR20020049043A (ko) 2002-06-24
CZ20021615A3 (cs) 2002-08-14
EA200200562A1 (ru) 2002-10-31
GEP20043267B (en) 2004-06-25
US6605600B1 (en) 2003-08-12
DE60033310D1 (de) 2007-03-22
CA2390590A1 (en) 2001-05-17
ATE353328T1 (de) 2007-02-15
IL149486A0 (en) 2002-11-10
BR0015540A (pt) 2002-07-23
CN1187354C (zh) 2005-02-02
NZ519427A (en) 2003-08-29
PL198156B1 (pl) 2008-05-30
HK1049153B (zh) 2007-09-28
EP1775297A3 (en) 2008-12-03
HUP0203371A2 (hu) 2003-02-28
US20050222179A1 (en) 2005-10-06
SK6622002A3 (en) 2003-02-04
WO2001034604A2 (en) 2001-05-17
EP1230241B1 (en) 2007-02-07
WO2001034604A3 (en) 2002-01-10
NZ527918A (en) 2005-05-27
HK1049153A1 (en) 2003-05-02
US20080004293A1 (en) 2008-01-03
CA2390590C (en) 2010-03-16
HUP0203371A3 (en) 2005-02-28
MXPA02004795A (es) 2005-07-01
US20030225038A1 (en) 2003-12-04
DE60033310T2 (de) 2007-11-22
EA010260B1 (ru) 2008-06-30
IS6380A (is) 2002-05-10

Similar Documents

Publication Publication Date Title
YU33802A (sh) Policikloalkilpurini kao antagonisti adenozinskih receptora
YU33702A (sh) Antagonisti adenozinskih receptora i postupci za njihovu izradu
HK1082728A1 (en) Azabicyclo derivatives as muscarinic receptor antagonists
WO2002072536A8 (en) Urea derivatives having vanilloid receptor (vr1) antagonist activity
CA2275686A1 (en) Isoquinolinamine and phthalazinamine derivatives which interact with crf receptors
WO2001007431A3 (en) Benzothiophene derivatives